BioSymposium – Innovating Antibody Drug Conjugates: From Mechanisms to Market
October 9 @ 8:45 am - 5:30 pm AEDT
Event Navigation
Join us for an informative, full-day conference dedicated to the latest advancements in antibody drug conjugates (ADC), and the opportunities including and beyond its current role as one of the fastest growing anticancer drugs.
Explore the vast ADC landscape spanning mechanisms, R&D, cancer treatments and other applications, manufacturing market dynamics, patent strategies, financial and commercial considerations, and policies to accelerate innovation in this space and improve health outcomes.
With four in-depth expert panel discussions traversing the opportunities and challenges, the day aims to accelerate your learning and fast-track your connections, with up to 200 key professionals attending from across the entire sector: industry, manufacturers, researchers, government, and service providers supporting the development pipeline.
With plenty of networking opportunities, engage and fuel your growth, drive opportunities, and enrich your professional and personal development. By investing in and strategically managing your network, position yourself for success and create a robust foundation for your future.
Session themes:
Session one: Understanding ADCs – The fundamentals and emerging innovations
The opening session will address the ADC landscape, exploring historical development, mechanisms and emerging medical applications. Hear how Victorian innovators are progressing ADC R&D and overcoming local and global commercialisation barriers.
Session two: ADC adoption – Targeting cancer
A panel of speakers will explore the impactful role of ADCs to treat HER2-positive metastatic breast cancer, lymphoma and other malignancies. Utilising case studies, discover the clinical significance of the advancements which are shaping the future of cancer health care.
Session three: Expanding horizons – Markets, funding and the future
Showcasing expanding applications of ADCs beyond cancer treatment, gain insights about next-gen ADC drug development and pipeline for cancer antibodies, regulation and safety. Our speakers will also discuss funding opportunities, market dynamics and commercialisation lessons from global leaders, as well as building commercial advantage through a strong patent strategies.
Session four: Empowering future innovation – Policy, training and other enablers
The final session will address how to achieve long-term R&D, GMP manufacturing and innovation success in the ADC field through workforce training, strategy setting and policy changes. Explore the importance of connecting data, technology and analytics to optimise clinical trials, and understand how we prepare the next generation of scientists and professionals in this cutting-edge field.
What to expect:
- The latest updates from industry experts
- Engaging information for diverse audiences
- Dynamic panel Q&A sessions
- In-person networking opportunities with peers.
Who should attend?
- Scientists and clinicians engaging in cancer research, drug discovery programmes and pre-clinical and clinical trials
- Start-ups entrepreneurs
- Investors
- Health care providers, patient advocates and policy makers
- Professionals seeking to improve knowledge and foster connections.
Event details:
Date: Wednesday 9 October 2024
Time (AEDT):
8:15 am – 8:45am: Guest arrival and registration
8:45am – 5:30pm: Sessions 1 – 4
5:30pm – 6:30pm: Networking
Venue: Ian Wark Theatre, CSIRO, Research Way, Clayton VIC 3168
Host: Karen Parr, CEO, BioMelbourne Network
Registration (Early bird rate):
In-person: Member $350; Non Member $500
Unsure if your organisation is a member? Check our member directory
2024 BioSymposium sponsors
Cancellation Policy
In-person registration:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
